<DOC>
	<DOCNO>NCT00489281</DOCNO>
	<brief_summary>RATIONALE : Giving low dos chemotherapy , fludarabine cyclophosphamide , total-body irradiation donor bone marrow transplant help stop growth abnormal cell . It also help stop patient 's immune system reject donor 's stem cell . When healthy stem cell donor infused patient may help patient 's bone marrow make stem cell , red blood cell , white blood cell , platelet . Sometimes transplanted cell donor make immune response body 's normal cell . Giving sirolimus mycophenolate mofetil transplant may stop happen . PURPOSE : This phase II trial study well give fludarabine cyclophosphamide together total-body irradiation follow donor bone marrow transplant work treat patient sickle cell anemia blood disorder .</brief_summary>
	<brief_title>Fludarabine , Cyclophosphamide , Total-Body Irradiation Followed By Donor Bone Marrow Transplant Treating Patients With Sickle Cell Anemia Other Blood Disorders</brief_title>
	<detailed_description>OBJECTIVES : - Determine transplant-related mortality progression-free survival patient severe hemoglobinopathy receive nonmyeloablative conditioning comprise fludarabine phosphate , cyclophosphamide , total-body irradiation follow partially HLA-mismatched bone marrow transplantation first-degree relative HLA-matched donor . - Characterize donor hematopoietic chimerism 30 , 60 , 180 day transplantation patient . - Determine hematologic non-hematologic toxicity regimen patient . OUTLINE : - Preparative regimen : Patients receive fludarabine phosphate IV 30 minute day -6 -2 cyclophosphamide IV 1-2 hour day -6 -5 . Patients also undergo total-body irradiation day -1 . - Bone marrow transplantation : Patients undergo allogeneic bone marrow transplantation day 0 . Patients receive cyclophosphamide IV 1-2 hour day 3 4 . - Graft-versus-host disease prophylaxis : Patients receive sirolimus orally daily day 5-365 oral mycophenolate mofetil 3 time day day 5-35 . After completion study treatment , patient follow periodically . PROJECTED ACCRUAL : A total 50 patient accrue study .</detailed_description>
	<mesh_term>Anemia , Sickle Cell</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Etiracetam</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis 1 follow sickle cell anemia ( Hb SS ) : Hb S/β° thalassemia Hb S/β+ thalassemia Hb SC disease Hb SE disease Hb SD disease Hemoglobin SOArab disease Hb S/hereditary persistence fetal hemoglobin Meets 1 follow criterion : History invasive pneumococcal disease Stroke CNS event last &gt; 24 hour MRI change indicative brain parenchymal damage Evidence cerebrovascular disease magnetic resonance angiography Acute chest syndrome require exchange transfusion hospitalization Recurrent vasoocclusive pain crisis ( &gt; 2 per year last 2 year ) Stage I II sickle lung disease Sickle retinopathy Osteonecrosis Red cell alloimmunization ( &gt; 2 antibody ) longterm transfusion Constellation dactylitis first year life AND baseline hemoglobin &lt; 7 g/dL leukocytosis ( WBC &gt; 13.4/mm^3 ) absence infection second year life Pitted RBC count &gt; 3.5 % first year life Ineligible refuse bone marrow transplantation HLAmatched sibling donor Partially mismatch ( least haploidentical ) firstdegree relative donor available No minor ( donor antirecipient ) ABO incompatibility ABO compatible donor available PATIENT CHARACTERISTICS : ECOG performance status ( PS ) 01 OR Karnofsky Lansky PS 70100 % LVEF ≥ 35 % FEV_1 force vital capacity ≥ 40 % predict Direct bilirubin &lt; 3.1 mg/dL No moderate severe pulmonary hypertension ECHO No debilitate medical psychiatric illness would preclude study participation No HIV positivity Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : No prior transfusion donor No immunosuppressive agent , include steroid antiemetic , within 24 hour last dose posttransplantation cyclophosphamide</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>sickle cell disease</keyword>
</DOC>